Talquetamab is a bsAb that targets CD3 and G-protein coupled receptor family C group 5 member D (GPRC5D), a recently identified MM antigen that is highly expressed on malignant MM cells and lowly expressed on hair follicles, but not on other healthy cells. Here, GPRC5D is linked to Miyoshi myopathy.